La Jolla Pharmaceutical Company (LJPC) stock price, revenue, and financials

La Jolla Pharmaceutical Company market cap is $150 m, and annual revenue was $23.05 m in FY 2019
View Company

$150 M

LJPC Mkt cap, 20-Jan-2021

$5.8 M

La Jolla Pharmaceutical Company Revenue Q2, 2020
La Jolla Pharmaceutical Company Gross profit (Q2, 2020)5 M
La Jolla Pharmaceutical Company Gross profit margin (Q2, 2020), %86.1%
La Jolla Pharmaceutical Company Net income (Q2, 2020)-15.6 M
La Jolla Pharmaceutical Company EBIT (Q2, 2020)-12.5 M
La Jolla Pharmaceutical Company Cash, 30-Jun-202068.4 M
La Jolla Pharmaceutical Company EV109.6 M

La Jolla Pharmaceutical Company Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.1m616.0k10.1m23.1m

Cost of goods sold

1.6m2.4m

Gross profit

8.4m20.7m

Gross profit Margin, %

84%90%

R&D expense

177.0k1.4m4.4m9.9m29.1m62.3m84.6m117.3m85.3m

General and administrative expense

2.1m9.4m13.6m11.4m13.9m16.7m30.9m85.2m45.1m

Operating expense total

2.3m10.7m17.9m21.3m43.0m79.0m115.4m202.5m130.5m

EBIT

(2.3m)(10.7m)(17.9m)(21.3m)(42.0m)(78.4m)(115.4m)(194.1m)(109.8m)

EBIT margin, %

(3971%)(12723%)(1930%)(476%)

Interest expense

6.7m

Interest income

1.9m2.1m

Income tax expense

Net Income

(11.5m)(7.7m)(17.9m)(21.3m)(41.9m)(78.2m)(114.8m)(199.5m)(116.5m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

647.0k234.0k253.0k44.0k809.0k1.6m3.5m4.4m5.7m5.7m7.6m5.8m

Cost of goods sold

58.0k129.0k256.0k500.0k551.0k554.0k716.0k808.0k

Gross profit

751.0k1.5m3.2m3.9m5.2m5.2m6.9m5.0m

Gross profit Margin, %

93%92%93%89%90%90%91%86%

R&D expense

177.0k34.0k474.0k655.0k700.0k948.0k2.0m1.6m2.6m5.2m6.7m7.8m12.7m12.4m17.0m17.8m20.8m19.1m28.4m30.9m30.4m21.2m22.0m21.2m9.2m8.8m

General and administrative expense

727.0k423.0k637.0k3.0m3.5m2.5m3.2m3.1m2.7m2.4m3.8m4.0m3.4m4.1m3.5m4.3m5.5m6.0m7.4m23.0m22.2m21.1m12.3m11.3m10.8m8.2m8.7m

Operating expense total

904.0k423.0k671.0k3.4m4.2m3.2m4.2m5.1m4.3m5.1m9.0m10.7m11.1m16.7m15.9m21.3m23.3m26.8m26.5m51.4m53.0m51.6m33.6m33.4m32.0m17.3m17.5m

EBIT

(904.0k)(423.0k)(671.0k)(3.4m)(4.2m)(3.2m)(4.2m)(5.1m)(4.3m)(5.1m)(9.0m)(10.7m)(10.5m)(16.5m)(15.6m)(21.3m)(23.3m)(26.8m)(26.5m)(50.7m)(51.6m)(48.4m)(29.7m)(28.2m)(26.8m)(10.5m)(12.5m)

EBIT margin, %

(1621%)(7057%)(6173%)(48402%)(6266%)(3237%)(1394%)(675%)(495%)(470%)(138%)(215%)

Interest expense

1.2m2.4m2.0m2.2m2.4m1.9m3.1m

Interest income

713.0k604.0k501.0k190.0k32.0k

Net Income

4.7m3.6m5.3m(2.2m)(4.2m)(3.2m)(4.2m)(5.1m)(4.3m)(5.1m)(9.0m)(10.6m)(10.5m)(16.5m)(15.6m)(21.3m)(23.2m)(26.7m)(26.3m)(50.5m)(52.8m)(50.7m)(31.7m)(30.4m)(29.2m)(8.6m)(15.6m)

La Jolla Pharmaceutical Company Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.0m3.4m8.6m48.6m126.5m65.7m90.9m172.6m87.8m

Accounts Receivable

1.4m3.0m

Prepaid Expenses

60.0k25.0k43.0k618.0k1.4m3.1m5.1m4.5m

Inventories

2.0m2.2m

Current Assets

5.1m3.4m8.7m50.3m127.5m67.4m94.1m181.1m97.5m

PP&E

2.2m38.0k279.0k1.7m3.1m24.6m22.3m18.4m

Total Assets

5.1m3.4m8.7m50.5m129.3m70.8m119.5m204.3m132.2m

Accounts Payable

8.0k92.0k834.0k730.0k2.5m6.7m11.5m8.6m4.2m

Short-term debt

Current Liabilities

15.5m216.0k1.1m2.1m4.8m9.8m18.6m30.4m24.6m

Long-term debt

124.3m26.5m

Total Debt

124.3m26.5m

Total Liabilities

31.3m168.4m188.2m

Common Stock

1.0k4.0k2.0k2.0k2.0k2.0k3.0k3.0k

Additional Paid-in Capital

424.1m439.7m462.7m528.4m646.4m661.1m803.1m950.3m977.4m

Retained Earnings

(439.6m)(447.4m)(465.3m)(486.6m)(528.5m)(606.7m)(721.5m)(921.0m)(1.0b)

Total Equity

(15.6m)3.2m7.7m48.5m124.5m61.0m88.2m35.9m(56.0m)

Financial Leverage

-0.3 x1.1 x1.1 x1 x1 x1.2 x1.4 x5.7 x-2.4 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

5.8m5.5m4.4m3.8m3.4m2.7m1.8m10.7m5.9m3.9m54.1m42.7m36.0m135.1m113.1m100.6m85.0m162.4m141.3m120.8m154.4m241.4m204.3m140.0m123.4m104.8m77.2m68.4m

Accounts Receivable

372.0k1.5m2.0m1.9m1.4m3.6m1.8m

Prepaid Expenses

19.0k9.0k50.0k97.0k40.0k76.0k67.0k47.0k156.0k148.0k153.0k622.0k622.0k484.0k1.4m1.4m1.4m1.7m1.8m1.8m6.3m5.3m5.8m5.1m5.1m4.8m3.4m2.8m

Inventories

820.0k2.0m2.0m1.9m2.0m3.1m

Current Assets

5.8m5.5m4.4m3.9m3.4m2.8m1.9m10.8m6.1m4.1m54.3m44.8m37.2m136.1m114.7m102.3m86.7m164.4m144.0m123.5m161.6m248.0m212.8m149.1m132.4m112.9m86.1m79.2m

PP&E

37.0k37.0k51.0k89.0k114.0k659.0k1.5m1.8m2.0m2.3m2.6m3.6m4.6m6.5m24.4m24.2m23.3m21.3m20.4m19.5m16.0m12.8m

Total Assets

5.8m5.5m4.4m3.9m3.4m2.8m2.0m10.8m6.1m4.2m54.4m45.5m38.7m137.9m117.0m104.8m89.5m168.0m148.6m130.1m186.9m273.1m237.1m187.8m169.9m149.1m118.2m107.4m

Accounts Payable

26.0k23.0k36.0k129.0k68.0k69.0k176.0k473.0k562.0k917.0k683.0k2.5m1.8m2.6m2.4m2.3m2.0m4.2m5.9m6.2m7.3m6.1m6.6m3.0m4.9m5.3m1.9m2.5m

Short-term debt

2.8m2.9m

Current Liabilities

6.9m2.6m9.7m14.0m12.9m271.0k308.0k577.0k906.0k1.1m1.6m2.6m2.5m4.3m5.2m5.2m7.2m5.7m8.3m10.3m16.0m19.0m23.9m17.2m22.0m22.5m16.0m17.9m

Long-term debt

28.6m27.9m27.2m25.7m25.0m

Total Debt

28.6m27.9m27.2m28.6m27.9m

Total Liabilities

29.5m157.5m162.1m176.5m182.5m184.3m179.9m182.6m

Common Stock

3.0k6.0k4.0k5.0k5.0k2.0k3.0k21.0k4.0k4.0k4.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k

Preferred Stock

3.6m3.6m3.6m

Additional Paid-in Capital

423.5m424.0m420.2m422.7m425.3m443.2m445.1m458.8m467.2m471.1m525.9m531.9m535.8m643.7m650.2m653.5m657.5m785.6m790.4m796.1m922.8m933.8m943.9m959.9m966.4m973.0m980.3m982.4m

Retained Earnings

(429.9m)(426.3m)(434.3m)(442.0m)(444.3m)(451.6m)(454.7m)(458.9m)(470.4m)(474.7m)(479.8m)(495.6m)(506.2m)(516.7m)(545.0m)(560.6m)(581.8m)(630.0m)(656.7m)(683.0m)(772.0m)(824.8m)(875.6m)(952.5m)(982.9m)(1.0b)(1.0b)(1.1b)

Total Equity

(6.4m)(2.3m)(10.6m)(15.7m)(15.3m)2.5m1.7m10.2m5.2m3.1m52.8m43.0m36.2m133.6m111.8m99.6m82.3m162.3m140.3m119.8m157.4m115.7m75.0m11.3m(12.6m)(35.2m)(61.7m)(75.2m)

Financial Leverage

-0.9 x-2.4 x-0.4 x-0.2 x-0.2 x1.1 x1.2 x1.1 x1.2 x1.3 x1 x1.1 x1.1 x1 x1 x1.1 x1.1 x1 x1.1 x1.1 x1.2 x2.4 x3.2 x16.6 x-13.5 x-4.2 x-1.9 x-1.4 x

La Jolla Pharmaceutical Company Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(11.5m)(7.7m)(17.9m)(21.3m)(41.9m)(78.2m)(114.8m)(199.5m)(116.5m)

Depreciation and Amortization

5.0k17.0k347.0k730.0k1.3m4.4m4.6m

Accounts Receivable

(1.4m)(1.6m)

Inventories

(2.0m)(191.0k)

Accounts Payable

31.0k(49.0k)822.0k(104.0k)1.8m3.6m4.8m(2.9m)(4.4m)

Cash From Operating Activities

(1.8m)(2.1m)(4.7m)(12.9m)(25.2m)(58.7m)(84.9m)(152.4m)(84.9m)

Purchases of PP&E

(43.0k)(258.0k)(1.8m)(2.2m)(9.2m)(2.3m)(698.0k)

Cash From Investing Activities

(43.0k)(258.0k)(1.8m)(2.2m)(9.2m)(2.3m)(698.0k)

Cash From Financing Activities

500.0k10.0m53.1m104.9m149.0k119.3m236.4m864.0k

Net Change in Cash

(1.8m)(1.6m)5.2m39.9m77.9m(60.7m)25.2m81.7m(84.8m)

Interest Paid

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.8m)1.8m5.3m(2.4m)(4.6m)(4.2m)(7.4m)(11.5m)(5.1m)(9.4m)(14.5m)(9.0m)(19.6m)(30.1m)(16.5m)(32.0m)(53.3m)(23.2m)(50.0m)(76.3m)(50.5m)(103.3m)(154.1m)(31.7m)(62.1m)(91.3m)(8.6m)(24.2m)

Depreciation and Amortization

1.0k3.0k2.0k5.0k10.0k11.0k95.0k209.0k142.0k310.0k510.0k281.0k581.0k899.0k992.0k2.1m3.2m1.1m2.3m3.4m1.1m1.8m

Accounts Receivable

(372.0k)(1.5m)(618.0k)(512.0k)(36.0k)(592.0k)1.1m

Inventories

43.0k52.0k110.0k251.0k(909.0k)

Accounts Payable

(92.0k)(43.0k)28.0k121.0k60.0k46.0k68.0k322.0k(197.0k)(46.0k)562.0k1.7m1.1m1.8m(98.0k)(250.0k)(508.0k)(2.5m)(732.0k)(413.0k)(4.2m)(5.4m)(4.9m)(5.5m)(3.7m)(3.2m)(2.3m)(1.7m)

Cash From Operating Activities

(1.1m)(1.4m)(659.0k)(1.2m)(1.7m)(705.0k)(1.5m)(2.6m)(2.7m)(4.7m)(7.5m)(5.5m)(11.2m)(16.7m)(13.0m)(25.1m)(40.1m)(22.1m)(41.9m)(60.4m)(45.8m)(83.4m)(120.3m)(32.7m)(49.2m)(67.8m)(12.2m)(20.6m)

Purchases of PP&E

(38.0k)(40.0k)(15.0k)(56.0k)(86.0k)(391.0k)(1.3m)(1.7m)(478.0k)(910.0k)(1.4m)(750.0k)(2.0m)(4.3m)(994.0k)(1.9m)(2.3m)(184.0k)(441.0k)(679.0k)

Cash From Investing Activities

(38.0k)(77.0k)(15.0k)(56.0k)(86.0k)(391.0k)(1.3m)(1.7m)(478.0k)(910.0k)(1.4m)(750.0k)(2.0m)(4.3m)(994.0k)(1.9m)(2.3m)(184.0k)(441.0k)(679.0k)1.1m(139.0k)

Dividends Paid

(374.0k)374.0k

Cash From Financing Activities

10.0m53.1m57.0k57.0k104.9m85.0k85.0k85.0k119.6m119.6m119.8m110.3m235.8m236.0m283.0k484.0k661.0k505.0k964.0k

Net Change in Cash

(1.1m)(1.4m)(659.0k)(1.2m)(1.7m)(705.0k)(1.6m)7.3m(2.7m)(4.7m)45.5m(5.8m)(12.5m)86.5m(13.4m)(25.9m)(41.4m)96.7m75.6m55.1m63.5m150.5m113.4m(32.6m)(49.2m)(67.8m)(10.6m)(19.8m)

La Jolla Pharmaceutical Company Ratios

USDQ2, 2011

Financial Leverage

-0.9 x
View La Jolla Pharmaceutical Company profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more